MedTrace Logo

Biomarkers in Neurodegenerative Diseases

NCT04055532 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-11-12

No results posted yet for this study

Summary

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

Conditions

  • Mild Cognitive Impairment (MCI)
  • Alzheimer Disease (AD)
  • Dementia With Lewy Bodies (DLB)
  • Frontotemporal Lobar Degeneration (FTLD)
  • Parkinsons Disease With Dementia (PDD)
  • Transient Epileptic Amnesia (TEA)
  • Temporal Lobe Epilepsy (TLE)
  • Spinocerebellar Ataxias (SCA)
  • HIV Associated Neurocognitive Disorder (HAND)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Primary Lateral Sclerosis (PLS)

Interventions

OTHER

Neuraceq

Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.

Sponsors & Collaborators

Principal Investigators

  • Keith Vossel, MD, MSc · University of Minnesota

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2024-10-01
Completion
2025-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04055532 on ClinicalTrials.gov